Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

36 results about "Suicide gene" patented technology

A suicide gene, in genetics, will cause a cell to kill itself through apoptosis. Activation of these genes can be due to many processes, but the main cellular "switch" to induce apoptosis is the p53 protein. Stimulation or introduction (through gene therapy) of suicide genes is a potential way of treating cancer or other proliferative diseases. Suicide genes form the basis of a strategy for making cancer cells more vulnerable, more sensitive to chemotherapy. The approach has been to attach parts of genes expressed in cancer cells to other genes for enzymes not found in mammals that can convert a harmless substance into one that is toxic to the tumor. Most suicide genes mediate this sensitivity by coding for viral or bacterial enzymes that convert an inactive drug into toxic antimetabolites that inhibit the synthesis of nucleic acid. Suicide genes must be introduced into the cells in ways that ensure their uptake and expression by as many cancer cells as possible, while limiting their expression by normal cells. Suicide gene therapy for cancer requires the vector to have the capacity to discriminate between target and non target cells, between the cancer cells and normal cells.

CD8 antibody modified anti-TIM-3 lipid nanoparticle, preparation method and application thereof

The invention provides a CD8 antibody modified anti-TIM-3 lipid nanoparticle as well as a preparation method and application thereof, and belongs to the technical field of medical preparations. The lipid nanoparticle contains a chimeric antigen receptor; the chimeric antigen receptor comprises a single-chain antibody TIM-3; the nucleic acid artificial sequence of the single-chain antibody TIM-3 is as shown in SEQ ID NO. 5. According to the application, sequence optimization is carried out on a TIM-3 target spot, a CAR structure connected with a double-stimulating factor and a suicide gene is prepared, and anti-TIM-3 nano-lipid particles modified by a CD8 antibody are constructed and delivered into cells, so that CD8 + T cells can be effectively captured in a body, CAR-T cells can be generated, a complex process of in-vitro preparation is omitted, and the application has the advantages of simplicity, convenience in operation and high efficiency. The activation degree of T cells is improved while the antigen is efficiently recognized, the efficient anti-tumor effect is achieved, the survival time of breast cancer mice is obviously prolonged, and the growth of tumors is inhibited.
Owner:SHANDONG RES INST OF ADULT CELL IND TECH CO LTD

Elimination of PD-l1-positive malignancies by PD-l1 chimeric antigen receptor-expressing NK cells

To provide an effective cancer therapy that targets both the tumor cells and the cells in the tumor microenvironment.SOLUTION: A recombinant NK-92 cell comprises a recombinant nucleic acid encoding a recombinant chimeric antigen receptor (CAR) that binds to PD-L1, an Fc receptor, and a suicide gene, wherein the recombinant NK-92 cell expresses the CAR and the Fc receptor on its surface.SELECTED DRAWING: Figure 2
Owner:IMMUNITYBIO INC

Engineering suicide gene approaches to improve chemotherapeutic response in cancer

Disclosed are compositions and methods for treating a disease or disorder such as cancer in a subject in need thereof. In some embodiments, the methods include administering to the subject a vector that has a first nucleic acid sequence encoding a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by kinase activity in a target cell and / or tissue. In some embodiments, the target cell and / or tissue can be a cell and / or tissue undergoing a stress response. In some embodiments, the target cell and / or tissue can be a cell and / or tissue in which a CK2 kinase is active. The kinase activity can be elevated extracellular regulated kinase (ERK) activity, p38 MAP kinase activity, and / or CK2 activity.
Owner:UNIV OF VIRGINIA PATENT FOUND

Chemo-sensitive dominant clone for adaptive therapy

Disclosed herein is a system that addresses all of the current challenges described above by combining three existing technologies and an improved nuclear RNA delivery system to generate a first-in-class cellular therapy that can secrete a cancer specific suicide gene for the treatment of several cancers. Also disclosed herein is a 'Trojan-Horse' like genetic construct aimed at engineering a chemo-sensitive dominant clone for adaptive therapy in cancers, such as leukemia. In some embodiments, cells, such as cancer cells from a subject, are engineered with suicide genes to promote a bystander effect in neighboring cancer cells once returned to the subject. In some embodiments, these cells are further engineered to be clonally dominant, e.g. by deleting or mutating tumor suppressor genes in the cells, overexpressing oncogenes, or any combination thereof. Once the engineered cells have reached a target clonal dominance, the suicide gene can be induced, thereby promoting the bystander effect.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Novel screening system for activators and inhibitors of signaling pathways based on cell death and life phenotypes

This invention provides a novel screening method for signaling pathway activators and inhibitors based on cell viability / death phenotypes. Specifically, this invention provides genetically engineered cells that enable large-scale screening of signaling pathway activators and inhibitors based on the expression of protective and suicide genes driven by signaling pathway transcription factors. The viability / death phenotype reporter system is effective and convenient for screening drugs affecting signaling pathways and can be applied to high-throughput screening in the early stages of drug development.
Owner:CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI

Methods and compositions for selectively eliminating cells of interest

The present disclosure provides novel compositions and methods suitable for specifically eliminating target cells (e.g., cancer cells) without affecting non-target cells (e.g., non-cancer cells). For example, CRISPR system and the compositions of the present disclosure can be employed to specifically introduce a suicidal gene into a cancer cell in the loci of a cancer-specific target sequence, which as a result of chromosomal re-arrangement or translocation in a cancer cell presents a cancer specific sequence for a guide RNA and CAS to be recognized and such sequence is absent in a non-cancer cell. Consequently, the specific introduction of the composition(s) to cancer-specific site(s) and integration of suicide gene in the target genome, which is inapplicable to normal cells for lack of the site(s), leads to selective elimination of cancer cells but not non-cancer cells, and therefore render novel therapeutic methods and compositions for cancer treatment.
Owner:ZHU JAMES

Streptococcus zooepidemicus gene deletion strain, live vaccine and preparation method thereof

PendingCN120025956ABacterial antigen ingredientsAntibacterial agentsStreptococcus zooepidemicusStreptococcus infection
The invention is applicable to the technical field of gene engineering, and is characterized in that a streptococcus zooepidemicus ATCC 35246 strain is used as a parent strain, and a pSET4S temperature-sensitive suicide gene knockout plasmid is utilized to knock out pyrroline-5-carboxylic acid reductase gene (proC), so that a streptococcus zooepidemicus gene deleted strain ATCC 35246 delta proC is obtained. The deletion strain has low toxicity, and when the mutant strain is used for immunizing a mouse in a large dose of viable bacteria, the titer of an antibody in the mouse can be obviously increased, and targeted immune protection is successfully established; the ATCC 35246 delta proC is convenient to prepare, low in cost and simple to culture, does not need other complex treatment when being used as a vaccine, and can be used after being adjusted to a corresponding concentration after bacteria washing. A result of an immune experiment on a mouse shows that the vaccine can effectively stimulate the immune level of an animal body and resist streptococcus zooepidemicus infection, and the deletion strain is high in safety and remarkable in immune protection effect in the mouse and has the potential of serving as a streptococcus zooepidemicus live vaccine.
Owner:NANJING AGRICULTURAL UNIVERSITY

Method to produce conditionally apoptotic cells

The method to produce conditionally apoptotic cells comprises modifying a cell population with a phenotype attributable to human adipose tissue-derived pericytes (AD-PC) expressing anti-tumor TRAIL introducing a sequence coding a conditional suicide gene (CSG).
Owner:EIR BIOTHERAPIES SRL

Truncated domain iv EGFR and uses thereof

A truncated EGFR (tEGFR) cell surface molecule and its uses is provided herein. The tEGFR cell surface molecule includes an EGFR domain IV and does not include an EGFR domain III and may be used, inter alia, as an in vivo tracking marker for genetically modified human T cells. Furthermore, the tEGFR cell surface molecule has cellular depletion potential through mediated through specific anti-domain IV EGFR antibodies. Thus, the tEGFR cell surface molecules provided herein may, inter alia, be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential.
Owner:CITY OF HOPE

Transformant and method for producing target protein

PCT designated stage expiredWO2025084267A1FungiBacteriaProtein targetGene
Provided is a transformant used for producing a target protein in vitro, in which a gene that encodes the target protein and a suicide gene have been introduced into a host cell. Also provided is a method for producing a target protein, the method comprising: a culture step in which the transformant is cultured in the presence of a cell death inducer that cooperates with a protein encoded by the suicide gene of the transformant to induce the cell death of the transformant, thereby producing a target protein; and a recovery step in which the target protein is recovered from the culture after the culture step.
Owner:TOKYO UNIVERSITY OF SCIENCE

Truncated epiderimal growth factor receptor (EGFRt) for transduced t cell selection

A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways. Thus, EGFRt may be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential.
Owner:CITY OF HOPE

HLA class I MHC cell excision

This invention provides compositions and methods for reducing the immunogenicity of cells for transplantation, including cell-based immunotherapy. [Solution] A vector encoding β2-microglobulin (B2M) modified RNA, along with a targeting moiety and other signaling and / or suicide genes, enables the efficient generation of engineered CAR T regulatory cells or other therapeutic cells derived from any source. The present invention provides, for example, vectors encoding β2-microglobulin (B2M) modified RNA and chimeric antigen receptors (CARs).
Owner:AZTHERAPIES INC

Armored chimeric antigen receptor t cells

The present application relates to sequences for expression in engineered chimeric antigen receptor (CAR) T cells for targeting IL13Ra2. In some embodiments, the sequences include a humanized VHH binder specific to IL13Ra2, an intracellular signaling domain, armoring elements to support cell persistence and functionality, or any combination thereof. Also disclosed herein are T cells that include a suicide gene for controlled cell elimination, and therapeutic uses thereof.
Owner:CHIMERIS UK LTD +1

Her2-based suicide switch

The present application relates to a suicide gene system and its use as part of immunotherapy. In some embodiments, the suicide gene system is expressed in a CAR T-cell, optionally along with armoring proteins. The present application also discloses uses of the suicide gene system, such as in cell tracking, immune regulation, rapid elimination of CAR T-cells, and as part of a therapeutic treatment.
Owner:CHIMERIS UK LTD +1

CASP9 suicide gene safety switch controlled by teton system and construction thereof

PCT designated stageWO2026002063A1HydrolasesMammal material medical ingredientsDimerT-cell apoptosis
The present invention provides a CASP9 suicide gene safety switch controlled by a TetOn system and construction thereof. Specifically, the present invention provides a coiled coil-CASP9 fusion protein whose expression is regulated by a tetracycline-inducible system. A dimer or multimer is formed by means of a coiled-coil sequence, so that Caspase-9 has cleavage activity, thereby inducing CAR-T cell apoptosis. The present invention has the effects of reducing adverse reactions and improving safety during CAR-T therapy.
Owner:XUZHOU MEDICAL UNIVERSITY

Safe and controllable chimeric antigen receptor loaded with suicide gene, macrophages expressing same and application thereof

The application uses gene editing technology to design and optimize a safe and controllable chimeric antigen receptor loaded with a suicide gene, and a macrophage expressing the same, the chimeric antigen receptor comprising a single-chain variable region targeting carcinoembryonic antigen (CEA), a hinge region, a transmembrane region, and an intracellular signaling region. The application has the following advantages: the chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M has high infiltration, enhanced phagocytosis and antigen presentation capacity, and is expected to become a new strategy for the immunotherapy of solid tumor cells. The constructed stem progenitor cells proliferate rapidly, can be obtained in large quantities in a short time, and can be frozen for long-term preservation. The induction of macrophages is short, simple and convenient, the macrophages efficiently express CAR, are stable and uniform, small molecule compounds regulate the fate of progenitor cells and macrophages, are safe and controllable, and have an anti-colorectal cancer treatment effect. The CAR-Hoxb8-M combined with an immune checkpoint inhibitor can further inhibit tumor growth and improve survival rate.
Owner:NANJING UNIV

AAV-mediated suicide gene therapy for the treatment of breast cancer

PCT designated stage expiredWO2025041154A1VectorsFermentationEfficacyOncology
The present invention provides a gene therapy strategy for an effective breast cancer treatment Employing Adeno-associated virus (AAV) vectors, the present invention delivers an inducible Casp9 (iCasp9) suicide transgene, specifically triggering apoptosis in breast cancer cells irrespective of their cell cycle phase. The innovative approach of the present invention presents heightened cytotoxicity within heterogeneous tumor tissues, and its compatibility with combinatorial treatments amplifies its therapeutic potential. Leveraging the inherent safety of AAV vectors, this therapy minimizes the likelihood of drug resistance emergence. Demonstrated efficacy in inhibiting tumor growth and inducing apoptosis in preclinical breast cancer models underscores the promise of this AAV-mediated iCasp9 gene therapy as a transformative solution, poised to revolutionize breast cancer treatment with improved efficacy and reduced systemic toxicity.
Owner:INDIAN INSTITUTE OF TECHNOLOGY KANPUR

Methods and compositions for treatment of hydrocephalus

PCT designated stageWO2025193755A1Organic active ingredientsNervous disorderCerebrospinal fluidApoptosis
Disclosed are compositions and methods for the treatment of hydrocephalus, for example pediatric hydrocephalus. The disclosed methods employ a non-surgical tool that may be used to control CSF production rate by inducing choroid plexus-specific apoptosis. In aspects, the non-surgical tools employ an AAV vector, a promoter, a suicide gene, and a suicide gene activator to achieve targeted choroid-plexus ablation and subsequent reduction of CSF volume.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +1

Engineering suicide gene approaches to improve chemotherapeutic response in cancer

Disclosed are compositions and methods for treating a disease and / or disorder such as cancer in a subject in need thereof. In some embodiments, the method includes administering to the subject a nucleic acid construct that includes a first nucleic acid sequence having a promoter operably linked to each of a second nucleic acid sequence encoding a therapeutic polypeptide, and a third nucleic acid sequence encoding a peptide domain that is stabilized when phosphorylated by stress-activated kinase activity in a target cell and / or tissue. In some embodiments, the target cell and / or tissue is a cell and / or tissue undergoing a stress response. In some embodiments, the kinase activity is stress-activated kinase activity mediated by p38 / MAP14 kinase activity, INK activity, or both.
Owner:UNIV OF VIRGINIA PATENT FOUND

Engineered immune cells expressing a car and a plurality of protein expression blockers and uses thereof

The present invention provides one or more expression vectors encoding one or more of an anti-CD7 chimeric antigen receptor (CAR), an anti-CD7 protein expression blocker, a kill gene or a suicide gene, and an anti-CD3 protein expression blocker. Also provided are immune cells comprising the one or more expression vectors. Also provided are methods of producing such one or more expression vectors or immune cells. Also provided are methods of using such one or more expression vectors or immune cells for treating cancer while reducing symptoms of Graft-versus-host disease (GvHD).
Owner:IASO BIOTHERAPEUTICS USA LTD

Enhancing activity of cell therapy in tumor microenvironments

Embodiments of the present disclosure include improving cell therapy by making cells more effective for cancer therapy, including in solid tumor microenvironments. In particular cases, the cells are modified to reduce or inhibit the expression levels of GPR4, GPR31, GPR68, GPR81, GPR132, GPR151, CREM, ICER, or CREB1, such as by CRISPR gene editing. In some cases, the cells are modified to reduce or inhibit the expression level of CREM. In some cases, the cells are further modified to express, for example, one or more engineered receptors, one or more cytokines, and / or optionally one or more suicide genes.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Truncated domain iv EGFR and uses thereof

A truncated EGFR (tEGFR) cell surface molecule and its uses is provided herein. The tEGFR cell surface molecule includes an EGFR domain IV and does not include an EGFR domain III and may be used, inter alia, as an in vivo tracking marker for genetically modified human T cells. Furthermore, the tEGFR cell surface molecule has cellular depletion potential through mediated through specific anti-domain IV EGFR antibodies. Thus, the tEGFR cell surface molecules provided herein may, inter alia, be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential.
Owner:CITY OF HOPE

Gene therapeutic vector for KSHV-associated diseases

PCT designated stageWO2026055462A1VectorsPeptide/protein ingredientsDiseaseMalignancy
Disclosed are compositions and methods for the treatment of KSHV-infected malignancies through administering an AAV gene therapy vector. The AAV vector encodes two copies of the TR sequence, a gene promoter and a suicide gene. The gene therapy vector leads to tumor cell apoptosis and further reactivation of KSHV transactivator to further activate therapeutic genes.
Owner:RGT UNIV OF CALIFORNIA

DNA, expression vector, transcript, cell, pharmaceutical composition, and medicine

An object of the invention is to provide a novel pharmaceutical composition. The pharmaceutical composition of the disclosure contains a DNA encoding a suicide gene having at least one intron sequence. The intron sequence has a donor sequence or an acceptor sequence to be used in a tumor cell with abnormal splicing not in a normal cell. In a transcript of the DNA, the suicide gene is expressed when the intron is abnormally spliced and the suicide gene is not expressed when the intron is not abnormally spliced.
Owner:HITACHI LTD

Composition for inhibiting tumor cells as well as preparation and application thereof

The invention discloses a composition for inhibiting tumor cells as well as preparation and application thereof. The composition comprises a protein or nucleic acid of Escherichia coli cytosine deaminase (CD), and a protein or nucleic acid of transmembrane protein CD63. The transmembrane protein CD63 of the exosome is utilized to autonomously wrap the protein and RNA of the suicide gene CD into the exosome, so that the drug loading rate is increased. The growth of human non-small cell lung cancer cells is successfully inhibited by detecting the proliferation condition of target cells after the 5-Fc drug is added.
Owner:ANHUI TONGKE BIOTECHNOLOGY CO LTD

Safe and controllable chimeric antigen receptor loaded with suicide gene, macrophage expressing same and application

The invention designs, optimizes and provides a safe and controllable chimeric antigen receptor loaded with a suicide gene and a macrophage for expressing the chimeric antigen receptor by applying a gene editing technology. The chimeric antigen receptor comprises a single-chain variable region, a hinge region, a transmembrane region and an intracellular signal region of a targeted carcino-embryonic antigen (CEA). The chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M has the advantages that the chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M has efficient wettability, the phagocytic ability and antigen presentation ability are enhanced, and the chimeric antigen receptor-Hoxb8 macrophage CAR-Hoxb8-M is expected to become a new strategy for solid tumor cell immunotherapy. The constructed stem progenitor cells are rapid in proliferation, can be massively obtained in a short time, can be cryopreserved for a long time, and are short in macrophage induction cycle, simple and convenient, the macrophages efficiently express CAR and are stable and uniform, small molecule compounds regulate the progenitor cells and macrophage fate, safety and controllability are achieved, and the anti-colorectal cancer treatment effect is achieved. The CAR-Hoxb8-M is combined with an immune checkpoint inhibitor, so that tumor growth can be further inhibited, and the survival rate can be increased.
Owner:NANJING UNIV

CASP9 suicide gene safety switch controlled by TetOn system and construction thereof

PendingCN121227805AHydrolasesMammal material medical ingredientsDimerT-cell apoptosis
The invention provides a CASP9 suicide gene safety switch controlled by a TetOn system and construction of the CASP9 suicide gene safety switch. Specifically, the invention provides a coiled helic-CASP9 fusion protein regulated and expressed by a tetracycline induction system, and a dimer or multimer is formed through a coiled helical sequence, so that Caspase-9 has cleavage activity so as to induce CAR-T cell apoptosis. The invention has the efficacy of reducing adverse reaction and improving safety in the process of CAR-T therapy.
Owner:XUZHOU MEDICAL UNIVERSITY

Compositions comprising a tweak ligand and methods of using same

The instant disclosure relates to nanoparticle compositions that may be used for the targeting of certain cells or tissues. The nanoparticles may take a variety of different forms, including non-viral, viral, and lipid nanoparticles, and may utilize a TNF receptor superfamily member 12A (“TWEAKR”) binding region of the TWEAK protein to target a nanoparticle to tissues expressing TWEAKR. The compositions may further comprise a suicide gene optionally under the control of a tissue specific promoter. In further aspects, methods of treating an individual using the disclosed nanoparticle compositions are described.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI +2

Secreted RNA therapeutics for nuclear delivery

Disclosed herein is a system that addresses the current challenges described by combining three existing technologies and an improved nuclear RNA delivery system to generate a first-in-class cellular therapy that can secrete a cancer specific suicide gene for the treatment of several cancers. The system generally involves a first poly nucleotide encoding retroviral elements that preferentially binds and facilitates formation and secretion of vesicles carrying its own RNA messenger operably linked to a first expression control sequence; a second polynucleotide encoding an RNA therapeutic having a nuclear retention sequence that is flanked by packaging signals for the retroviral elements operably linked to a second expression control sequence; and a third polynucleotide encoding a membrane fusion protein operably linked to a third expression control sequence.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC

Method for producing cell population containing genetically modified mesenchymal stem cells

The present invention addresses the problem of providing a method for producing genetically modified amnion-derived mesenchymal stem cells by introducing a suicide gene into amnion-derived mesenchymal stem cells. Provided is a method for producing a cell population including genetically modified amnion-derived mesenchymal stem cells, the method comprising a step for genetically introducing a suicide gene or a suicide gene expression cassette into a cell population containing amnion-derived mesenchymal stem cells through a method in which a plasmid vector is used, such as the transposon method.
Owner:KANEKA CORP